US › Healthcare

Ovid Therapeutics Inc (OVID)

US · Healthcare · Biotechnology

$2.54+9.01%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-17.0M
Profit YoY
-66.0%
EPS
$-0.12
EPS estimate
$-0.11

EPS came in at -0.12 against a street estimate of -0.11 — a miss of 9.1%.

Key statistics

Market cap
$414.3M
Forward P/E
1.8
P/B
2.07
Book value
$1.19
EPS (TTM)
$-0.21
52-week high
$3.10
52-week low
$0.48
50-day MA
$2.45
200-day MA
$2.04
Beta
0.19

Analyst view

Analysts rate Ovid Therapeutics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $5.47.

Shareholding

Insiders
7.04%
Institutions
64.49%

Largest institutional holders

FundStake
HHG PLC6.19%
RA Capital Management, LLC6.19%
Affinity Asset Advisors, LLC6.15%
Eventide Asset Management, LLC5.73%
Adage Capital Partners Gp LLC3.56%
Balyasny Asset Management LLC3.20%
Vanguard Capital Management, LLC3.04%
ADAR1 Capital Management LLC2.63%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ovid Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.